Gastrointestinal symptoms in COVID-19 could be associated with severe lung involvement and increased readmission rates

Basit Öğe Kaydı
dc.authoridBilen, Omer/0000-0001-7198-8421en_US
dc.authoridBozkurt, Hüseyin S/0000-0003-2097-2950en_US
dc.contributor.authorBozkurt, Hüseyin S.
dc.contributor.authorBilen, Omer
dc.date.accessioned2024-07-12T21:37:27Z
dc.date.available2024-07-12T21:37:27Z
dc.date.issued2021en_US
dc.department[Belirlenecek]en_US
dc.description.abstractIntroduction SARS-CoV-2 virus manifests itself with primary lung damage but also has intestinal involvement. In this study, we aimed to investigate the frequency of gastrointestinal symptoms (GIS) and the relationship of GIS with readmission to the hospital within 30 days in SARS-CoV-2 infected patients who were hospitalized in a specified pandemic hospital. Materials and Methods Symptomatic patients diagnosed with rapid antibody positivity with real-time polymerase chain reaction and typical thorax computed tomography findings were included in this retrospective cohort observational study. Demographic and clinical data were obtained from electronic medical records. Hospital-associated GIS were considered as experiencing at least one of the GIS such as gas, bloating, diarrhea, and constipation developing within72 h after hospital admission. Results The mean age of the patients was 58 +/- 14.4 years and 60.7% were men. 82% of hospitalizations were a moderate and severe disease. 71.4% of patients without GIS had at least one of the GIS after hospitalization. As the severity of the disease increased, the frequency of the severity of gastrointestinal symptom increased. GIS bowel disorders were more prominent in patients with moderate and severe disease. Antibiotic and specific treatment (anti-Il-1, anti-Il-6) contributed to the occurrence of gastrointestinal symptom in SARS-CoV-2 inpatients. Conclusion According to our observations of the second wave of the pandemic, the presence, frequency, and severity of gastrointestinal symptom in inpatient is associated with severity of lung disease and increased readmission rate after discharge.en_US
dc.identifier.doi10.1177/20587392211048259
dc.identifier.issn1721-727X
dc.identifier.issn2058-7392
dc.identifier.scopus2-s2.0-85115741651en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.urihttps://doi.org/10.1177/20587392211048259
dc.identifier.urihttps://hdl.handle.net/20.500.12415/6771
dc.identifier.volume19en_US
dc.identifier.wosWOS:000702281100001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherSage Publications Incen_US
dc.relation.ispartofEuropean Journal of Inflammationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKY04113
dc.subjectSars-Cov-2en_US
dc.subjectGastrointestinal Symptomen_US
dc.subjectPneumoniaen_US
dc.titleGastrointestinal symptoms in COVID-19 could be associated with severe lung involvement and increased readmission ratesen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu